// App-Quantinova.ai

OC 15.1 : PREVAPIX-ALL: Phase 3 Study of the Safety and Efficacy of Apixaban for Thromboprophylaxis versus Standard of Care in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia or Lymphoma (ALL/LL)

Researchers

Presenter

  • S. O'Brien

Principal Investigators

  • V. Rodriguez

  • C. Schultz

  • M. Ranalli

  • H. Kang

  • M. Donovan

  • L. Mitchell

Medical Centers

  • Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital & The Ohio State University, Colulmbus, Ohio, United States

  • Nationwide Children's Hospital & The Ohio State University, Columbus, Ohio, United States

  • Bristol Myers Squibb, Princeton, New Jersey, United States

  • Department of Cardiology, Boston Children's Hospital & Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States

  • Nemours Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, United States

  • The Saban Research Institute, Childrens Hospital Los Angeles, Los Angeles, California, United States

  • Department of Pediatric Oncology, Geisinger, Danville, Pennsylvania, United States

  • Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital & The Ohio State University, Colulmbus, Ohio, United States

  • Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, Tennessee, United States

  • Department of Dermatology, New York Medical College, Valhalla, NY, United States

  • Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute& Wide River Institute of Immunology, Seoul National University Children's Hospital, Seoul, Kyonggi-do, Republic of Korea

  • Department of Chemotherapy for Oncohematological Diseases and Bone Marrow Transplantation for Children, Almazov National Medical Research Centre, Saint Petersburg, Saint Petersburg City, Russia

  • Bristol Myers Squibb, Inc., Lawrence Township, New Jersey, United States

  • Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada

Locations

  • United States

  • Republic of South Korea

  • Russia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Asparaginase

  • apixaban

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved